Patients With ALK+ Lung Cancer Given Targeted Therapy
This roundtable series reviews the treatment of patients with advanced ALK-positive non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
April 26th 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
